EVCF II’s first participation Equflow acquired by Saint-Gobain Life Sciences
Eindhoven Venture Capital Fund II (EVCFII) invested in Equflow in 2018 to allow the company to scale up and achieve its intended growth. That was a success. Now Saint-Gobain Life Sciences has announced the acquisition of Equflow.
Equflow is a leading developer and supplier of flow meters, manufactured for a wide variety of commercial and industrial applications. Primarily serving the single use bioprocessing market. The acquisition expands Saint-Gobain’s product capabilities within its Bio-Process Solutions (BPS) business.
“We are delighted to welcome Equflow to our organization and are excited about the opportunities this addition creates for our customers,” said Jean Angus, President and CEO of Saint-Gobain Life Sciences. “While we see opportunities to leverage Equflow’s fluid metering technologies across all of our businesses, we especially want to expand our single-use capabilities.” With some inherent overlap of customers and geographies, the addition of Equflow’s flowmeters and sensors to Saint-Gobain’s BPS portfolio complements its single-use fluid management solutions.
“It was important for us to find a partner who understands our applications, customers and markets,” says Daniël van Beek, CEO of Equflow BV. “With Saint-Gobain, we know we have the support and expertise of a global manufacturer, while maintaining our ability to innovate and create custom solutions that meet our customers’ needs.”
About Saint-Gobain Life Sciences
Committed to improving the quality of life, Saint-Gobain Life Sciences develops and manufactures high-quality components and integrated solutions related to a wide range of patient care. From the development of new therapeutic cancer treatments to biopharmaceutical manufacturing, to intravenous therapies for drug delivery.
For more information please visit the website of Saint-Gobain Life Sciences.